ArticleCancer medicine2026
Management and Outcomes of Uterine Smooth Muscle Tumour of Uncertain Malignant Potential (STUMP).
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUterine smooth muscle tumours of uncertain malignant potential (STUMP) is a mesenchymal tumour which does not fulfil the criteria for leiomyoma, benign histological subtypes, or leiomyosarcoma. The risk factors for recurrence and the rates of recurrence vary amongst different studies; as a result, there are currently no consensus guidelines for optimal management.
methodsPatients diagnosed with STUMP that were treated in a tertiary medical centre in Hong Kong were included in the study. The clinical and histological features were analysed and reviewed. Any adjuvant treatment was documented. Follow-up information, results of imaging studies and outcomes were obtained.
resultsThirty-four patients with a diagnosis of STUMP were identified between 2002 and 2020. Three patients presented with atypical presentations including genital prolapse, an ovarian tumour and a fibroid polyp. Thirteen patients (38.2%) were diagnosed after abdominal myomectomy, 19 (55.6%) after a hysterectomy and 2 (6.2%) after other surgical procedures. Ten patients (66.6%) had a hysterectomy after primary surgery. Our patients were followed up every 3-6 months for the first 5 years then yearly with a median follow-up period of 6.5 years. Three patients (12.5%) developed a recurrence, all were leiomyosarcoma. The mean time for recurrence was 7.6 years. Four patients (30.7%) did not have a hysterectomy following a myomectomy and remained free of recurrence.
conclusionClinical and pathological factors influencing the risk of recurrence remain uncertain. With the lack of significant data, prognostic information and recommendations on follow up, management of these patients and their outcomes need to be further pooled and elaborated. This retrospective observational study reports the clinical course of this disease at a tertiary referral centre in Hong Kong.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.